This report provides the risks and opportunities in China and South Africa for a Pharmaceutical Company seeking to expand its operations to one of these two countries. The report finds that China is risky for the company despite the high population. The Chinese market is riddled with stringent policies and laws which are meant to limit foreign companies in the country. The level of corruption, shrinking economic growth and development, rising costs of production and labor are the challenges that the company is likely to face in China. Cultural differences and stringent control of the financial system in China are also risks that the company may face.